Skip to main content
A

ApicHope Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 300723 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,589 across all filing types
Latest filing 2026-04-23 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300723

About ApicHope Pharmaceutical Group Co.,Ltd

https://www.gdyph.com

ApicHope Pharmaceutical Group Co., Ltd. is a comprehensive enterprise dedicated to the research, development, manufacturing, and commercialization of pharmaceutical products. The company maintains a strategic focus on pediatric medicine, offering a diverse portfolio of specialized formulations for children, including treatments for respiratory, digestive, and infectious diseases. In addition to its pediatric leadership, the group develops medications for chronic conditions, cardiovascular health, and the central nervous system. ApicHope operates advanced production bases that integrate the manufacturing of active pharmaceutical ingredients (APIs) with finished dosage forms. Its R&D efforts are centered on clinical demand and innovative drug delivery systems to enhance therapeutic efficacy. The organization utilizes a robust marketing and distribution infrastructure to deliver healthcare solutions across multiple therapeutic categories.

Recent filings

Filing Released Lang Actions
第四届董事会第十七次会议决议公告
Regulatory Filings Classification · 1% confidence The document is a formal announcement of board of directors’ meeting resolutions (a “董事会决议公告”) filed on the stock exchange, detailing items approved and vote outcomes. It does not itself constitute an annual or interim report, nor an earnings release, proxy statement, or director/shareholder vote declaration. It also does not announce changes in board composition (so not MANG). As a general regulatory filing that doesn’t neatly fit other specific categories, it is best classified as a Regulatory Filing (RNS).
2026-04-23 Chinese
2025年度财务决算报告
Audit Report / Information Classification · 1% confidence The document is titled “2025年度财务决算报告” and immediately presents an auditor’s standard unqualified opinion followed by detailed balance sheet, income statement, and cash flow statement line by line. It does not include broad business narrative, governance, or management discussion sections typical of a full Annual Report (10-K), nor is it a short notice or summary. Instead, it is a standalone audited financial report, matching the definition of an Audit Report/Information (AR).
2026-04-23 Chinese
2025 年度营业收入扣除情况的专项审核报告
Regulatory Filings
2026-04-23 Chinese
关于审计委员会对会计师事务所履行监督职责情况的报告
Regulatory Filings
2026-04-23 Chinese
董事会关于独立董事独立性情况的专项意见
Governance Information Classification · 1% confidence The document is a board-issued “special opinion” on the independence of its two independent directors, conducted under listing rules and corporate governance regulations. It is not announcing a managerial change, financial figures, or a report publication; rather, it details the company’s governance practice regarding independent directors. This aligns with the Governance Information category (CGR).
2026-04-23 Chinese
2025年年度报告
Regulatory Filings
2026-04-23 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.